ArticleBMC neurology2026
Establishing PDK1-based prognostic biomarkers and identifying targeted inhibitors for glioma prognosis and therapy.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGlioma patients face a poor prognosis with limited therapeutic benefits from conventional treatments. PDK1, has emerged as a critical molecular target for glioma-specific therapy. We investigated PDK1’s role in glioma progression, developed a prognostic model (PDK1_PS) for survival prediction, and identified Taxiresinol as a novel PDK1 inhibitor with potent anti-tumor activity, while Glycerol tribenzoate was identified as a potential binder requiring further structural optimization.
methodRNA-seq and clinical data of 160 glioblastoma samples were obtained from TCGA and stratified by PDK1 expression. Immune-related signatures were quantified by ssGSEA, and downstream differentially expressed genes were identified for functional enrichment. A PDK1-associated prognostic signature (PDK1_PS) was constructed using LASSO Cox regression and validated in the CGGA cohort. Structure-based virtual screening was performed against the ATP-binding pocket of PDK1, followed by ADME/TOPKAT evaluation, molecular docking, pharmacophore characterization, and 100 ns molecular dynamics simulations using Discovery Studio 2019 and Gromacs. Candidate compounds were assessed in vitro experiments.
resultPDK1 stratification was associated with distinct immune programs and transcriptional patterns. A five-gene PDK1_PS showed prognostic value in the training cohort and maintained performance in CGGA validation. Virtual screening nominated Taxiresinol (ZINC000034189841) and glycerol tribenzoate (ZINC000001577210) as promising binders, supported by docking and dynamic stability analyses. In vitro, Taxiresinol showed a clear dose-dependent anti-proliferative effect in U87 cells, whereas glycerol tribenzoate showed limited cytotoxicity within the tested range and warrants further evaluation.
conclusionThis study establishes a PDK1-related prognostic signature and identifies Taxiresinol and glycerol tribenzoate as candidate PDK1-targeting compounds supported by in silico binding analyses. Further mechanistic validation (e.g., kinase activity and downstream phosphorylation) is needed to confirm on-target effects and advance translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.